A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

Prior treatment

• Participant has had a thymectomy within 6 months prior to Baseline
• Current or recent systemic infection within 2 weeks prior to Baseline or infection requiring intravenous antibiotics within 4 weeks prior to Baseline

Other illness

• Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study

Other

• Participant has known positive serology for muscle-specific kinase
• Participant has minimal Manifestation Status of MG based on the clinical judgement of the Investigator

• United States of America (USA) specific inclusion criterion:
• \- Participant must be 12 to \<18 years of age at the time of signing the Informed consent/assent according to local regulation
• Rest of world (ROW) specific inclusion criterion:
• \- Participant must be 2 to \<18 years of age at the time of signing the Informed consent/assent according to local regulation
• Global inclusion criteria:
• Participant has a diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR) prior to Screening
• Participant meets the criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening
• Participants with gMG, including:
• An MG-activities of daily living (MG-ADL) total score of 6 or more in adolescents from 12 years to \<18 years of age at Screening
• Documented weakness in at least 1 limb, neck, or bulbar muscle in children from 2 years to \<12 years of age at Screening (does not apply to US)
• Documented vaccination against meningococcal infections within 3 years prior to study start. If not fully vaccinated, participants must receive appropriate prophylactic antibiotic treatment until at least 2 weeks after the initial dose of vaccine(s)